Vitiligo
MONDO:0008661Generalized well circumscribed patches of leukoderma that are generally distributed over symmetric body locations and is due to autoimmune destruction of melanocytes.
136 clinical trials for this condition and its sub-types, 100 tagged with Vitiligo itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vitiligo
-
Generalized vitiligo 16 trials
-
Trichrome vitiligo 0 trials
-
Can a weekend steroid pill stop vitiligo spreading in kids?
Disease control CompletedThis study tests whether taking dexamethasone pills twice a week for 3 months can stop active vitiligo from spreading in children aged 4 to 9. Researchers will also monitor side effects, especially on growth and bone health. The goal is to control the disease, not cure it.
Phase 4 • Sponsor: Cairo University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a blood flow drug help restore skin color in vitiligo?
Disease control CompletedThis trial tests whether a topical medication called pentoxifylline, typically used to improve blood flow, can help restore skin color in people with stable vitiligo. It compares this approach to another topical drug, 5-fluorouracil, and to microneedling alone, with all patients …
Sponsor: Tanta University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can your own fat cells help restore skin color in vitiligo?
Disease control CompletedThis trial tests whether injecting a specially processed form of a patient's own fat tissue, called nanofat, can improve repigmentation in stable vitiligo when combined with standard narrowband UVB light therapy. In each of 20 adults, one vitiligo patch receives nanofat plus ligh…
Sponsor: Benha University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Fat stem cells and light may restore skin color in vitiligo
Disease control CompletedThis study tests whether injecting a person's own fat-derived stem cells into stable vitiligo patches, alone or combined with excimer light therapy, can safely bring back skin color. Fifteen adults with stable vitiligo patches will receive the treatment. The goal is to see if the…
Sponsor: Tanta University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lamp vs laser: which light works best for vitiligo?
Disease control CompletedThis study compared two types of ultraviolet light treatments—an excimer lamp and an excimer laser—for repigmenting white patches caused by vitiligo. Adults with at least two matching patches of vitiligo received both treatments on different patches twice a week for 12 weeks. The…
Phase 3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a drug plus light therapy reverse vitiligo? new trial tests the combo
Disease control CompletedThis phase 2 trial tested whether adding the oral drug baricitinib to phototherapy (light treatment) helps restore skin color in adults with progressive vitiligo. 49 participants received either baricitinib plus phototherapy or a placebo plus phototherapy for 36 weeks. The main g…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New ointment shows promise for restoring skin color in vitiligo
Disease control CompletedThis phase 2 trial tested an ointment called MH004 in 156 people with non-segmental vitiligo, a condition that causes white patches on the skin. Participants applied the ointment to affected areas once or twice daily for 24 weeks. The study measured how much skin color returned, …
Phase 2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a common arthritis drug help stop vitiligo from spreading?
Disease control CompletedThis phase 2 trial tested whether adding methotrexate (a drug used for arthritis) to standard UVB light therapy works better than light therapy alone for adults with active, spreading vitiligo. Thirty-two participants were randomly assigned to receive either methotrexate pills pl…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody drug shows promise for vitiligo in early trial
Disease control CompletedThis phase 2a trial tested an experimental drug called AMG 714 in 60 adults with vitiligo, a condition that causes white patches on the skin. The drug works by blocking a protein called IL-15, which may play a role in the disease. Participants received either AMG 714 or a placebo…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a pill plus light therapy restore skin color in vitiligo?
Disease control CompletedThis study tested whether the drug apremilast, taken as a pill twice daily, combined with narrowband UVB light therapy can help restore skin color in people with widespread vitiligo. 80 adults with stable or slowly progressing vitiligo covering at least 10% of their body took par…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a cholesterol drug help stop vitiligo?
Disease control CompletedThis study tested whether adding the cholesterol drug atorvastatin to standard UVB light therapy works better than UVB alone for active vitiligo. 28 adults with active, non-segmental vitiligo took part. The main goal was to see if the combination reduced the amount of skin color …
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cream shows promise for genital vitiligo in early trial
Disease control CompletedThis phase 2 trial tested a cream called ruxolitinib (Opzelura) on 49 people with nonsegmental vitiligo affecting the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the white patches less noticeable. The study measured success based on p…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Can a daily pill bring back skin color? new trial tests ritlecitinib for vitiligo
Disease control CompletedThis Phase 3 study tested ritlecitinib, an oral drug, in 607 adults and adolescents with nonsegmental vitiligo (a type of white patches on the skin). Participants took either the drug or a placebo daily for 52 weeks. The main goals were to see if the drug could improve skin color…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Vitiligo showdown: new drug vs. old combo in Head-to-Head trial
Disease control CompletedThis study tested whether a newer cream (ruxolitinib) works better alone or when combined with two older creams (tacrolimus and corticosteroids) for vitiligo. 120 adults with limited vitiligo (less than 10% of body affected) were split into three groups and treated for 24 weeks. …
Phase 4 • Sponsor: Dow University of Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Could a common arthritis drug ease skin woes in down syndrome?
Disease control CompletedThis study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blue light therapy shows promise for vitiligo repigmentation
Disease control CompletedThis study compared blue light therapy to targeted narrow band UVB for treating stable non-segmental vitiligo in 30 patients. The goal was to see which treatment better restores skin color. Both are light-based therapies, but blue light may be less harsh on the skin.
Phase 4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 26, 2026 16:55 UTC
-
Can early UVB and steroids stop vitiligo in its tracks?
Disease control CompletedThis study tested whether starting treatment early with UVB light therapy and low-dose steroids can stop vitiligo from spreading and improve skin color return. 51 people with different stages of vitiligo were treated for 6 months. Researchers took skin samples to see how immune c…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
Can glutathione boost gum lightening? a Split-Mouth trial investigates
Symptom relief CompletedThis trial tests whether adding a glutathione gel to microneedling improves the lightening of dark gums compared to microneedling alone. Fifteen healthy adults with gum pigmentation will receive both treatments on different sides of their mouth to compare results. The study measu…
Sponsor: Krishnadevaraya College of Dental Sciences & Hospital • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Nano-Silver bandage promises quicker gum recovery after dark spot removal
Symptom relief CompletedThis study tested whether a nano-crystalline silver dressing helps gums heal faster and with less pain after surgical removal of dark gum pigmentation. Twelve adults with moderate to severe gum pigmentation had the surgery, and the silver dressing was compared to a standard dress…
Sponsor: Damascus University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Can an antioxidant boost light therapy for vitiligo?
Symptom relief CompletedThis study tested whether adding a special antioxidant pill (GLISODIN) to standard UVB light therapy helps treat vitiligo better than light therapy alone. Fifty adults with non-segmental vitiligo covering more than 5% of their body took part. The main goal was to see if the combi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Skin markers may reveal how light therapy fights vitiligo
Knowledge-focused CompletedThis study looks at whether a common light treatment for vitiligo changes certain proteins in the skin. Researchers will measure two markers, CD63 and CD9, in skin samples from 20 people with vitiligo before and after three months of narrow-band ultraviolet B (NB-UVB) therapy. Th…
Sponsor: Amany El-Agamy Ibrahim El-Samadony • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Skin biopsy study aims to unlock Vitiligo's repigmentation mystery
Knowledge-focused CompletedThis study compares skin samples from 20 people with vitiligo and 20 healthy volunteers to understand why certain body areas (like the face) repigment well while others (like hands and feet) do not. Researchers will analyze gene activity in skin from five different body sites. Th…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Vitiligo linked to higher risk of depression and anxiety in major study
Knowledge-focused CompletedThis study looked at over 36,000 adults in the UK to see if people with vitiligo are more likely to have mental health problems like depression, anxiety, or self-harm compared to those without vitiligo. Researchers used medical records to compare risks and also checked if these r…
Sponsor: Momentum Data • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New study reveals hidden toll of vitiligo on chinese patients
Knowledge-focused CompletedThis study looked at how vitiligo affects people in China, including their treatments and daily life. Researchers observed 100 patients to measure the disease's impact on their skin and quality of life. The goal was to better understand the real-world burden of this condition.
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC